{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:48:17Z","timestamp":1792619297551,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00210-025-04424-0","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T11:16:53Z","timestamp":1752664613000},"page":"16767-16778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of sotatercept in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis"],"prefix":"10.1007","volume":"398","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7334-9711","authenticated-orcid":false,"given":"Laila","family":"Shalabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehroze","family":"Tabassum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar M.","family":"Al Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosam I.","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Gowaily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abuelazm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"4424_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1183\/13993003.00879-2022","volume":"2023","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M et al (2022a) ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023:61. https:\/\/doi.org\/10.1183\/13993003.00879-2022","journal-title":"Eur Respir J"},{"key":"4424_CR2","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M et al (2022b) 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43:3618\u20133731. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237","journal-title":"Eur Heart J"},{"key":"4424_CR3","doi-asserted-by":"publisher","unstructured":"Santos RT, de S\u00e1 Freire Onofre ME, de Assis Fernandes Caldeira D, Klein AB, Rocco PRM, Cruz FF et al (2024) Pharmacological agents and potential new therapies in pulmonary arterial hypertension. Curr Vasc Pharmacol 22:155\u2013170. https:\/\/doi.org\/10.2174\/0115701611266576231211045731","DOI":"10.2174\/0115701611266576231211045731"},{"key":"4424_CR4","doi-asserted-by":"publisher","unstructured":"Hoeper MM, Pausch C, Gr\u00fcnig E, Staehler G, Huscher D, Pittrow D, et al (2022) Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J 59. https:\/\/doi.org\/10.1183\/13993003.02024-2021","DOI":"10.1183\/13993003.02024-2021"},{"key":"4424_CR5","doi-asserted-by":"publisher","unstructured":"Humbert M, Guignabert C, Bonnet S, Dorfm\u00fcller P, Klinger JR, Nicolls MR et al (2019) Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 53. https:\/\/doi.org\/10.1183\/13993003.01887-2018","DOI":"10.1183\/13993003.01887-2018"},{"key":"4424_CR6","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41467-021-21961-3","volume":"12","author":"GRT Ryanto","year":"2021","unstructured":"Ryanto GRT, Ikeda K, Miyagawa K, Tu L, Guignabert C, Humbert M et al (2021) An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension. Nat Commun 12:1720. https:\/\/doi.org\/10.1038\/s41467-021-21961-3","journal-title":"Nat Commun"},{"key":"4424_CR7","doi-asserted-by":"publisher","unstructured":"Guignabert C, Humbert M (2021) Targeting transforming growth factor-\u03b2 receptors in pulmonary hypertension. Eur Respir J 57. https:\/\/doi.org\/10.1183\/13993003.02341-2020","DOI":"10.1183\/13993003.02341-2020"},{"key":"4424_CR8","doi-asserted-by":"publisher","first-page":"814222","DOI":"10.3389\/fmed.2021.814222","volume":"8","author":"P Andre","year":"2021","unstructured":"Andre P, Joshi SR, Briscoe SD, Alexander MJ, Li G, Kumar R (2021) Therapeutic approaches for treating pulmonary arterial hypertension by correcting imbalanced TGF-\u03b2 superfamily signaling. Front Med (Lausanne) 8:814222. https:\/\/doi.org\/10.3389\/fmed.2021.814222","journal-title":"Front Med (Lausanne)"},{"key":"4424_CR9","doi-asserted-by":"publisher","unstructured":"Yung L-M, Yang P, Joshi S, Augur ZM, Kim SSJ, Bocobo GA et al (2020) ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension. Sci Transl Med 12. https:\/\/doi.org\/10.1126\/scitranslmed.aaz5660","DOI":"10.1126\/scitranslmed.aaz5660"},{"key":"4424_CR10","doi-asserted-by":"publisher","first-page":"7803","DOI":"10.1038\/s41598-022-11435-x","volume":"12","author":"SR Joshi","year":"2022","unstructured":"Joshi SR, Liu J, Bloom T, Karaca Atabay E, Kuo T-H, Lee M et al (2022) Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension. Sci Rep 12:7803. https:\/\/doi.org\/10.1038\/s41598-022-11435-x","journal-title":"Sci Rep"},{"key":"4424_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA et al (2020) statement: an updated guideline for reporting systematic reviews. BMJ 2021:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4424_CR12","doi-asserted-by":"crossref","unstructured":"Shalabi L, Abuelazm M (2025) Efficacy and safety of sotatercept in pulmonary arterial hypertension: a systematic review and meta-analysis . PROSPERO CRD420251031657. Available from\u00a0https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251031657","DOI":"10.1007\/s00210-025-04424-0"},{"key":"4424_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12874-024-02356-6","volume":"24","author":"A Abbas","year":"2024","unstructured":"Abbas A, Hefnawy MT, Negida A (2024) Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol 24:243. https:\/\/doi.org\/10.1186\/s12874-024-02356-6","journal-title":"BMC Med Res Methodol"},{"key":"4424_CR14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"4424_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"4424_CR16","unstructured":"Higgins JPT, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JAC (2019) Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. John Wiley & Sons p 257\u201361"},{"key":"4424_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","volume":"61","author":"J Wetterslev","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C (2008) Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 61:64\u201375. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.03.013","journal-title":"J Clin Epidemiol"},{"key":"4424_CR18","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","volume":"384","author":"M Humbert","year":"2021","unstructured":"Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR et al (2021) Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med 384:1204\u20131215. https:\/\/doi.org\/10.1056\/NEJMoa2024277","journal-title":"N Engl J Med"},{"key":"4424_CR19","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV et al (2023) Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 388:1478\u20131490. https:\/\/doi.org\/10.1056\/NEJMoa2213558","journal-title":"N Engl J Med"},{"key":"4424_CR20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415160","author":"M Humbert","year":"2025","unstructured":"Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M et al (2025) Sotatercept in patients with pulmonary arterial hypertension at high risk for death. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2415160","journal-title":"N Engl J Med"},{"key":"4424_CR21","doi-asserted-by":"publisher","first-page":"e51867","DOI":"10.7759\/cureus.51867","volume":"16","author":"N Uddin","year":"2024","unstructured":"Uddin N, Ashraf MT, Sam SJ, Sohail A, Ismail SM, Paladini A et al (2024) Treating pulmonary arterial hypertension with sotatercept: a meta-analysis. Cureus 16:e51867. https:\/\/doi.org\/10.7759\/cureus.51867","journal-title":"Cureus"},{"key":"4424_CR22","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.healun.2022.03.011","volume":"41","author":"MM Hoeper","year":"2022","unstructured":"Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Gr\u00fcnig E et al (2022) Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: a COMPERA analysis. J Heart Lung Transplant 41:971\u2013981. https:\/\/doi.org\/10.1016\/j.healun.2022.03.011","journal-title":"J Heart Lung Transplant"},{"key":"4424_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40259-024-00680-3","volume":"38","author":"B Stump","year":"2024","unstructured":"Stump B, Waxman AB (2024) Pulmonary arterial hypertension and TGF-\u03b2 superfamily signaling: focus on sotatercept. BioDrugs 38:743\u2013753. https:\/\/doi.org\/10.1007\/s40259-024-00680-3","journal-title":"BioDrugs"},{"key":"4424_CR24","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1016\/j.jacc.2019.02.066","volume":"73","author":"A Kempny","year":"2019","unstructured":"Kempny A, Dimopoulos K, Fraisse A, Diller G-P, Price LC, Rafiq I et al (2019) Blood viscosity and its relevance to the diagnosis and management of pulmonary hypertension. J Am Coll Cardiol 73:2640\u20132642. https:\/\/doi.org\/10.1016\/j.jacc.2019.02.066","journal-title":"J Am Coll Cardiol"},{"key":"4424_CR25","doi-asserted-by":"publisher","unstructured":"Souza R, Jardim C, Julio Cesar Fernandes C, Silveira Lapa M, Rabelo R, Humbert M (2007) NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med 101:69\u201375. https:\/\/doi.org\/10.1016\/j.rmed.2006.04.014","DOI":"10.1016\/j.rmed.2006.04.014"},{"key":"4424_CR26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1183\/09031936.00160307","volume":"32","author":"G Warwick","year":"2008","unstructured":"Warwick G, Thomas PS, Yates DH (2008) Biomarkers in pulmonary hypertension. Eur Respir J 32:503\u2013512. https:\/\/doi.org\/10.1183\/09031936.00160307","journal-title":"Eur Respir J"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04424-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04424-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04424-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T04:29:41Z","timestamp":1764822581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04424-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4424"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04424-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}